At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Crossover Study to Evaluate the Effects of Single Doses of MK-1064 and MK-6096 on Polysomnography (PSG)
In Brief
A Phase 1 clinical trial evaluating MK-1064, MK-6096, and 1 other intervention for Polysomnography. Completed, enrolled 20 participants.
Detailed Summary
The purpose of this randomized, double-blind, placebo-controlled, 5-period crossover study is to assess the effect of single oral doses of MK-1064 on latency to persistent sleep (LPS) as measured by polysomnography (PSG) in healthy young male participants, and to evaluate the safety and tolerability of single oral doses of MK-1064 and MK-6096 in healthy young male participants. The primary efficacy hypothesis is that at least one dose of MK-1064 is superior to placebo in decreasing LPS in healthy male participants as assessed by PSG.
Study Details
Timeline
Interventions
Oral MK-1064 tablets (10 and 50 mg strengths)
Oral MK-6096 tablets (5 mg strength)
Oral placebo tablets (matching active MK-1064 tablets, matching active MK-6096 tablets)